2022 - Cancer Currents Blog
-
Researchers have been developing artificial intelligence (AI) tools that could make cancer imaging faster, more accurate, and more informative. But there are also questions about whether these tools are ready for doctors’ offices, whether they will actually help people, and whether that benefit will reach all—or only some—patients.
-
Women are more likely than men to experience severe side effects from cancer treatments such as chemotherapy, targeted therapy, and immunotherapy, a new study finds. Researchers hope the findings will increase awareness of the problem and help guide patient care.
-
New results from a large study show that trametinib (Mekinist) is an effective treatment for low-grade serous ovarian cancer. The findings are the first strong evidence that this rare type of ovarian cancer should be treated differently from other forms of the disease.
-
Experts say studies are needed on how to best transition telehealth from a temporary solution during the pandemic to a permanent part of cancer care that’s accessible to all who need it.
-
As adults, survivors of childhood cancer aren’t any less likely to have healthy babies than those without a history of cancer, a new study shows. However, they may have more health risks during pregnancy, warranting more intensive obstetric care.
-
A nanoparticle coating may help cancer drugs reach medulloblastoma tumors in the brain and make the treatment less toxic. Mice treated with nanoparticles containing palbociclib (Ibrance) and sapanisertib lived substantially longer than those treated with either drug alone.
-
The rates of timely cervical cancer screening fell between 2005 and 2019, researchers found, and disparities existed among groups of women. The most common reason for not receiving timely screening was lack of knowledge about screening or not knowing they needed screening.
-
Removing immune cells called naive T cells from donated stem cells before they are transplanted may prevent chronic graft-versus-host disease (GVHD) in people with leukemia, a new study reports. The procedure did not appear to increase the likelihood of patients’ cancer returning.
-
Adding durvalumab (Imfinzi) to standard chemotherapy modestly extended how long people with advanced biliary tract cancer lived, results from the TOPAZ-1 trial show. The immunotherapy drug may now be the standard first-line therapy for this hard-to-treat cancer.
-
With the passage of the Air is Life Act of 2021, the Navajo Nation enacted the most comprehensive ban on commercial tobacco products of any American Indian tribe to date.